Although body mass index data were not available for this cohort, our findings suggest that any unmeasured obesity is likely to have been more prevalent in the GLP1 receptor agonist group, with any associated bias potentially moving the estimate towards increased risk of thyroid cancer. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.